This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

LCDR Kenneth M. Lankin, MD, MC USN
Naval Hospital Pensacola Pensacola, Fla

JAMA. 1997;278(11):897.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—The article by Dr Dong and collegues,¹ along with the accompanying letters and Editorial,² was a superb presentation regarding the controversy over the bioequivalence of levothyroxine preparations and the issues that arise when commercially supported research produces results that are at odds with the financial interests of corporate sponsors.

However, it was surprising to see 2 advertisements for Levoxyl-brand levothyroxine (formerly named Levoxine), manufactured by Jones Medical Industries Inc, 1 of the 4 thyroid preparations studied in the article by Dong et al that claims "any of the 4 preparations studied can be effectively used for levothyroxine replacement therapy." The advertisements tout the cost savings between their product, Levoxyl, and Synthroid and contain an unusual note of the company's stock symbol. The second advertisement is seemingly strategically placed only 4 pages after the Editorial.

It would be difficult to ascribe the sudden appearance of these ads, especially from . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?